Rectal Cancer - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 279

Rectal Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Rectal Cancer - Pipeline Review, H2 2012', provides an overview of the Rectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rectal Cancer. 'Rectal Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rectal Cancer.
- A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rectal Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Rectal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Rectal Cancer Therapeutic Products under Development, Key Players in Rectal Cancer Therapeutics, Rectal Cancer Pipeline Overview, Rectal Cancer Pipeline, Rectal Cancer Pipeline Assessment

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Rectal Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Rectal Cancer 10
Rectal Cancer Therapeutics under Development by Companies 12
Rectal Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Pre-Clinical Stage Products 24
Comparative Analysis 24
Rectal Cancer Therapeutics – Products under Development by Companies 25
Rectal Cancer Therapeutics – Products under Investigation by Universities/Institutes 26
Companies Involved in Rectal Cancer Therapeutics Development 34
F. Hoffmann-La Roche Ltd. 34
Abbott Laboratories 35
Sanofi-Aventis 36
Merck & Co., Inc. 37
ImClone Systems Incorporated 38
Merck KGaA 39
Zenotech Laboratories Limited 40
Corporacion Parc Tauli 41
Isofol Medical AB 42
Rectal Cancer – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
Stimuvax - Drug Profile 49
Rapamycin + Radiation Therapy - Drug Profile 51
Celecoxib - Drug Profile 52
Irinotecan + Capecitabine + Radiotherapy - Drug Profile 53
Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy - Drug Profile 54
Irinotecan + Cetuximab + Radiation Therapy - Drug Profile 56
Capecitabine + Sorafenib + Radiation Therapy - Drug Profile 57
Capecitabine + Radiation Therapy - Drug Profile 59
Capecitabine + Panitumumab + Radiation Therapy - Drug Profile 60
Oxaliplatin + Capecitabine + Radiation Therapy - Drug Profile 64
Celecoxib + Radiation Therapy - Drug Profile 66
Capecitabine + Oxaliplatin + Bevacizumab + Radiation Therapy - Drug Profile 68
Celebrex + 5-FU + Radiation Therapy - Drug Profile 70
5-Fluorouracil + Oxaliplatin + Calcium Folinate + Radiation Therapy - Drug Profile 71
Capecitabine + Radiation Therapy - Drug Profile 73
Erbitux + Capecitabine + Radiation Therapy - Drug Profile 74
Oxaliplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile 76
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 80
LMB-9 Immunotoxin - Drug Profile 82
Capecitabine + Irinotecan - Drug Profile 83
Capecitabine + Oxaliplatin - Drug Profile 85
FOLFOX + Radiation Therapy - Drug Profile 89
IMC-A12 + Irinotecan + Cetuximab - Drug Profile 91
UFT + Leucovorin + Irinotecan + Radiation - Drug Profile 92
XELOX + Radiotherapy - Drug Profile 94
Bevacizumab + Capecitabine + Radiotherapy - Drug Profile 95
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 97
Panitumumab + CAPOX - Drug Profile 99
Capecitabine + Bevacizumab + Radiation Therapy - Drug Profile 101
Oxaliplatin + 5-Fluorouracil + Radiotherapy - Drug Profile 103
Cetuximab - Drug Profile 104
Celebrex + Xeloda + Radiation Therapy - Drug Profile 105
FOLFIRI - Drug Profile 106
5-Fluorouracil + Folinic Acid - Drug Profile 108
Cetuximab + Irinotecan hydrochloride + Radiation Therapy - Drug Profile 109
Capecitabine + Panitumumab + Irinotecan + Radiation Therapy - Drug Profile 111
Bevacizumab + Xeloda + Radiotherapy - Drug Profile 113
Fluorouracil + Leucovorin Calcium + Radiation Therapy - Drug Profile 115
Oxaliplatin + Fluorouracil + Radiation Therapy - Drug Profile 116
Cetuximab + 5-Fluorouracil + Radiation Therapy - Drug Profile 117
Oxaliplatin + 5-Fluorouracil + Leucovorin + Radiation Therapy - Drug Profile 118
Oxaliplatin + Capecitabine + Celebrex + Radiation Therapy - Drug Profile 120
Panitumumab + 5-Fluorouracil + Radiation Therapy - Drug Profile 122
Ftorafur + Radiation Therapy - Drug Profile 129
Capecitabine + Panitumumab + Radiation Therapy - Drug Profile 130
Irinotecan + Capecitabine + Radiation Therapy - Drug Profile 134
mFOLFOX6 + Bevacizumab + Radiation Therapy - Drug Profile 136
Curcumin + Capecitabine + Radiation Therapy - Drug Profile 138
Fluorouracil + Oxaliplatin + Radiation Therapy - Drug Profile 139
Capecitabine + Radiation therapy - Drug Profile 141
Oxaliplatin + Capecitabine + Radiation Therapy - Drug Profile 143
Fluorouracil + Radiation Therapy - Drug Profile 145
Capecitabine + Radiation Therapy - Drug Profile 147
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 148
Celebrex+ Fluorouracil + Radiation Therapy - Drug Profile 149
Erbitux + Xeloda + Campto + Radiation Therapy - Drug Profile 151
Xelox + Bevacizumab - Drug Profile 153
Capecitabine + Radiation Therapy - Drug Profile 154
Capecitabine + Radiation Therapy - Drug Profile 155
FOLFOX + Radiation Therapy - Drug Profile 156
S-1 + Radiation Therapy - Drug Profile 158
Irinotecan + Capecitabine + Radiation Therapy - Drug Profile 159
UFT + PSK - Drug Profile 161
S-1 + Irinotecan + Radiation Therapy - Drug Profile 162
S-1 + Oxaliplatin + Radiation Therapy - Drug Profile 163
mFOLFOX6 + Bevacizumab - Drug Profile 164
TS-1 + CPT-11 + Cetuximab + Radiation Therapy - Drug Profile 166
TS-1 - Drug Profile 168
AZD6244 + Capecitabine + Radiation Therapy - Drug Profile 169
AZD2171 + Capecitabine + Radiation Therapy - Drug Profile 171
Xeloda - Drug Profile 173
Capecitabine + Radiation Therapy - Drug Profile 174
Capecitabine + Radiotherapy - Drug Profile 175
XELOX + Bevacizumab + Radiation Therapy - Drug Profile 176
Capecitabine + Radiation Therapy - Drug Profile 177
Capecitabine + Irinotecan + Celecoxib + Radiation Therapy - Drug Profile 178
Capecitabine + Radiation Therapy - Drug Profile 180
S-1 + Radiation Therapy - Drug Profile 181
UFT + Radiation Therapy - Drug Profile 182
TS-1 + Oxaliplatin + Radiation - Drug Profile 183
panitumumab + capecitabine - Drug Profile 184
panitumumab + capecitabine - Drug Profile 186
FOLFOX6 + Radiation Therapy - Drug Profile 188
XELOX - Drug Profile 190
5-Fluorouracil + Oxaliplatin - Drug Profile 191
Cetuximab + Capecitabine + radiation theraphy - Drug Profile 192
Capecitabine + Radiotherapy - Drug Profile 194
Rapamycin - Drug Profile 195
Capecitabine + Radiotherapy - Drug Profile 196
Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Calcium + Oxaliplatin - Drug Profile 197
C225 + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium - Drug Profile 199
Floxuridine + Gemcitabine Hydrochloride - Drug Profile 201
Celebrex + Fluorouracil + Radiation Therapy - Drug Profile 203
Capecitabine + AZD6244 + Radiation Therapy - Drug Profile 205
TS-1 + Oxaliplatin + Cetuximab + Radiation - Drug Profile 207
S-1 + Oxaliplatin + Bevacizumab + Radiotherapy - Drug Profile 209
Avastin + Xeloda + Fluorouracil + Leucovorin - Drug Profile 211
S-1 + Oxaliplatin + Radiation Therapy - Drug Profile 213
Leucovorin + High Dose Radiotherapy + UFT - Drug Profile 215
CAPOX + Radiation Therapy - Drug Profile 217
Capecitabine + Bevacizumab + Radiation Therapy - Drug Profile 218
Oxaliplatin + Leucovorin + Fluorouracil - Drug Profile 219
Capecitabine + Celecoxib + Radiation Therapy - Drug Profile 221
Oxaliplatin + Celecoxib + Radiation Therapy - Drug Profile 223
FOLFOX + Radiation Therapy - Drug Profile 225
Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Radiation Therapy - Drug Profile 227
Xeloda + Radiation Therapy - Drug Profile 229
Irinotecan + Xeloda + Oxaliplatin - Drug Profile 230
Modufolin + Alimta - Drug Profile 232
Capecitabine + Bevacizumab + Radiation Therapy - Drug Profile 235
Rifaximin - Drug Profile 236
PKC412 + 5-Fluorouracil - Drug Profile 237
FOLFIRINOX + Radiochemotherapy - Drug Profile 239
Modified FOLFOX6 + Chemoradiation - Drug Profile 241
Panitumumab - Drug Profile 243
Intensity Modulated Radiation Therapy + Bevacizumab + FOLFOX - Drug Profile 244
Sorafenib + 5-Fluorouracil + Radiation Therapy - Drug Profile 246
Capecitabine + Oxaliplatin + Bevacizumab + Radiation Therapy - Drug Profile 248
Nitroglycerin + 5-Flourouracil + Radiation Therapy - Drug Profile 250
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 252
Alimta - Drug Profile 254
Xelox + Radiation Therapy - Drug Profile 255
MK-0646 + Irinotecan - Drug Profile 257
Veliparib + Capecitabin - Drug Profile 258
Rectal Cancer Therapeutics – Drug Profile Updates 260
Rectal Cancer Therapeutics – Discontinued Products 261
Rectal Cancer Therapeutics - Dormant Products 262
Rectal Cancer – Product Development Milestones 267
Featured News & Press Releases 267
Appendix 269
Methodology 269
Coverage 269
Secondary Research 269
Primary Research 269
Expert Panel Validation 269
Contact Us 270
Disclaimer 270

List of Tables
Number of Products Under Development for Rectal Cancer, H2 2012 19
Products under Development for Rectal Cancer – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Investigation by Universities/Institutes, H2 2012 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 42
F. Hoffmann-La Roche Ltd., H2 2012 43
Abbott Laboratories, H2 2012 44
Sanofi-Aventis, H2 2012 45
Merck & Co., Inc., H2 2012 46
ImClone Systems Incorporated, H2 2012 47
Merck KGaA, H2 2012 48
Zenotech Laboratories Limited, H2 2012 49
Corporacion Parc Tauli, H2 2012 50
Isofol Medical AB, H2 2012 51
Assessment by Monotherapy Products, H2 2012 52
Assessment by Combination Products, H2 2012 53
Assessment by Stage and Route of Administration, H2 2012 55
Assessment by Stage and Molecule Type, H2 2012 57
Rectal Cancer Therapeutics – Drug Profile Updates 269
Rectal Cancer Therapeutics – Discontinued Products 270
Rectal Cancer Therapeutics – Dormant Products 271
Rectal Cancer Therapeutics – Dormant Products (Contd..1) 272
Rectal Cancer Therapeutics – Dormant Products (Contd..2) 273
Rectal Cancer Therapeutics – Dormant Products (Contd..3) 274
Rectal Cancer Therapeutics – Dormant Products (Contd..4) 275

List of Figures
Number of Products under Development for Rectal Cancer, H2 2012 19
Products under Development for Rectal Cancer – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 23
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 52
Assessment by Combination Products, H2 2012 53
Assessment by Route of Administration, H2 2012 54
Assessment by Stage and Route of Administration, H2 2012 55
Assessment by Molecule Type, H2 2012 56
Assessment by Stage and Molecule Type, H2 2012 57

Customers who bought this item also bought

• Adenocarcinoma - Pipeline Review, H2 2012
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, H2 2012
• Brain Metastasis - Pipeline Review, H2 2012
• Myeloproliferative Disorders - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Adenomas - Pipeline Review, H2 2012